Literature DB >> 11378377

Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.

L Schio1, F Chatreaux, V Loyau, M Murer, A Ferreira, P Mauvais, A Bonnefoy, M Klich.   

Abstract

A novel series of novobiocin analogues has been synthesised by removing the lipophilic aryl chain in novobiocin and introducing an amino substituent. The structural modifications have been dictated by the control of lipophilicity and the dissociation constant of the resulting compounds. Antibacterial activity of the new coumarin derivatives could be correlated with the amount of uncharged form in physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378377     DOI: 10.1016/s0960-894x(01)00257-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Thermodynamic computational approach to capture molecular recognition in the binding of different inhibitors to the DNA gyrase B subunit from Escherichia coli.

Authors:  Liane Saíz-Urra; Miguel Ángel Cabrera Pérez; Matheus Froeyen
Journal:  J Mol Model       Date:  2013-04-30       Impact factor: 1.810

2.  In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.

Authors:  Nagraj Mani; Christian H Gross; Jonathan D Parsons; Brian Hanzelka; Ute Müh; Steve Mullin; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Paul S Charifson; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.

Authors:  Arlyn Tambo-ong; Sidharth Chopra; Bryan T Glaser; Karen Matsuyama; Tran Tran; Peter B Madrid
Journal:  Bioorg Med Chem Lett       Date:  2011-08-12       Impact factor: 2.823

Review 4.  Coumarin-piperazine derivatives as biologically active compounds.

Authors:  Kinga Ostrowska
Journal:  Saudi Pharm J       Date:  2019-12-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.